Antiandrogen enzalutamide induced genetic, cellular, and hepatic damages: amelioration by triterpene Lupeol

Therapeutic implications of probiotics in microbiota dysbiosis: A special reference to the liver and oral cancers

(2021) Deepti Singh et al.   LIFE SCIENCES

Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer

(2020) Giuseppe Saltalamacchia et al.   Cancers

Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway

(2019) Konjeti R. Sekhar et al.   PLoS One

Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT)

(2019) Neal D. Shore et al.   Clinical Genitourinary Cancer

Apigenin, A Plant Flavone Playing Noble Roles in Cancer Prevention Via Modulation of Key Cell Signaling Networks

(2019) Deepti Singh et al.   Recent Patents on Anti-Cancer Drug Discovery

A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects

(2017) W. Krauwinkel et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Sulfasalazine induces mitochondrial dysfunction and renal injury

(2017) Hossein Niknahad et al.   RENAL FAILURE

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials

(2017) Raphael B. Moreira et al.   Oncotarget

Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress

(2016) M. Shiota et al.   ANNALS OF ONCOLOGY

Human Topoisomerase I mediated cytotoxicity profile of l -valine-quercetin diorganotin(IV) antitumor drug entities

(2016) Sabiha Parveen et al.   JOURNAL OF ORGANOMETALLIC CHEMISTRY

Clinical Pharmacokinetic Studies of Enzalutamide

(2015) Jacqueline A. Gibbons et al.   CLINICAL PHARMACOKINETICS

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mixed ligand–silver(i) complexes with anti-inflammatory agents which can bind to lipoxygenase and calf-thymus DNA, modulating their function and inducing apoptosis

(2012) C. N. Banti et al.   Metallomics

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy

(2011) Hifzur Rahman Siddique et al.   CLINICAL CANCER RESEARCH

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

(2010) Howard I Scher et al.   LANCET